Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Study Finds Workplace Health Care Significantly Increases Adherence To Medications, Potentially Saving Health Care Dollars
A new study shows that patients who use workplace primary care and pharmacy services have higher adherence rates to medications for chronic conditions, suggesting that by investing in integrated workplace health and pharmacy programs companies can realize health care savings while also improving patient outcomes.
generic viagra online
What Is Bell's Palsy? What Causes Bell's Palsy?
Bell"s palsy is either weakness or paralysis of the muscles on one side of the face due to malfunction of the facial nerve. It usually starts suddenly - somebody can wake up in the morning and find that one side of the face does not move. Sometimes one eyelid may be affected, meaning that the patient is unable to blink properly from one eye.
News of the day
Learning More About The Placebo Effect
In this trial, a sample of alcohol-dependent patients received naltrexone, acamprosate or placebo for 12 weeks. While there were no differences in outcomes between treatment groups, those who believed they had been taking active medication consumed fewer alcoholic drinks and reported less alcohol dependence and cravings. That is, irrespective of actual treatment, perceived medication allocation predicted health outcomes.
Public Health

Poniard Rally To Continue: Strong Efficacy And Safety Data From Picoplatin

Poniard announced positive Phase II data from its two trials in CRC and CRPC with picoplatin this morning, including efficacy that was comparable to the current standard of care, with a significantly improved safety profile. We believe that these data provide further evidence of picoplatin"s favorable efficacy and safety profile in two more large oncology markets, in addition to SCLC, and position picoplatin as a platform treatment that can provide solutions in multiple oncology settings. We believe that given these data from CRC and CRPC, in addition to the anticipated Phase III SPEAR data in SCLC, will attract the interest of multiple players and we expect that Poniard will be able to at least secure a large pharma partnership sometime this summer, unless a company like Sanofi (SNY Not Rated), Takeda (TKD Not rated), or Bristol-Myers Squibb (BMY Not Rated) decide to step in and acquire the whole company, for rights to both the IV and oral version of picoplatin. The CRC Phase II trial data. In this randomized Phase II trial, 101 chemo-naive metastatic CRC patients treated with picoplatin in the FOLPI regimen demonstrated median PFS of 6.8 months, versus 7.0 months in patients treated with the current standard of care, oxaliplatin-containing, FOLFOX-6 regimen, while exhibiting very similar disease control (75% vs. 76% respectively). The main differentiating factor between the two treatment regimens was the reduced occurrence of neuropathy (29% in FOLPI vs. 60% in FOLFOX6), including a statistically significant difference in Grade Âõ neuropathy (0% vs. in FOLPI vs. 16% in FOLFOX6, p-valueThe CRPC Phase II trial data. In this Phase II trial, 32 chemo-naïve CRPC patients treated with picoplatin in combination with docetaxel and prednisone, showed a 78% rate of PSA response, versus the 45% observed in the TAX-327 arm of q3w docetaxel. In addition, median PFS was 8.5 months, and 58% of the patients achieved disease control. On the safety front, there was no neurotoxicity observed, in contrast to what was observed in TAX-327, with 30% neuropathy, including 2% severe neuropathy. (See page 3 for a table describing these data) When and where can investors see these data? Poniard will present data at ASCO from these two Phase II trials testing A) picoplatin plus docetaxel/prednisone in patients with metastatic castration-resistant (hormone-refractory) prostate cancer (CRPC) (Abstract # 5140) on Sunday, May 31st (2-6pm ET, Level 2, West Hall C) and B) picoplatin plus 5-FU/leucovorin in patients with metastatic colorectal cancer (CRC) (Abstract # 4026) on Monday, June 1 (Poster session 8am-12pm ET, Level 2, W240A, with a discussion of the poster scheduled from 11:30 a.m. to 11:45 a.m. in West Hall E1, Level 2). Poniard


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009